We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Gilead Sciences Draws Complete Response Letter for Lenacapavir
Gilead Sciences Draws Complete Response Letter for Lenacapavir
The FDA has issued a Complete Response Letter (CRL) to Gilead Sciences for its new drug application (NDA) for lenacapavir, an HIV-1 capsid inhibitor for patients with HIV who are heavily treated and multidrug-resistant.